Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form

Nuclear receptor RORα regulates pathologic retinal angiogenesis by modulating SOCS3-dependent inflammation

Academic Article
uri icon
  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Sun, Y.
  • Liu, C. H.
  • SanGiovanni, J. P.
  • Evans, L. P.
  • Tian, K. T.
  • Zhang, B.
  • Stahl, A.
  • Pu, W. T.
  • Kamenecka, Theodore
  • Solt, Laura A.
  • Chen, J.

publication date

  • August 2015

journal

  • Proceedings of the National Academy of Sciences of the United States of America  Journal

abstract

  • Pathologic ocular angiogenesis is a leading cause of blindness, influenced by both dysregulated lipid metabolism and inflammation. Retinoic-acid-receptor-related orphan receptor alpha (RORα) is a lipid-sensing nuclear receptor with diverse biologic function including regulation of lipid metabolism and inflammation; however, its role in pathologic retinal angiogenesis remains poorly understood. Using a mouse model of oxygen-induced proliferative retinopathy, we showed that RORα expression was significantly increased and genetic deficiency of RORα substantially suppressed pathologic retinal neovascularization. Loss of RORα led to decreased levels of proinflammatory cytokines and increased levels of antiinflammatory cytokines in retinopathy. RORα directly suppressed the gene transcription of suppressors of cytokine signaling 3 (SOCS3), a critical negative regulator of inflammation. Inhibition of SOCS3 abolished the antiinflammatory and vasoprotective effects of RORα deficiency in vitro and in vivo. Moreover, treatment with a RORα inverse agonist SR1001 effectively protected against pathologic neovascularization in both oxygen-induced retinopathy and another angiogenic model of very-low-density lipoprotein receptor (Vldlr)-deficient (Vldlr (-/-) ) mice with spontaneous subretinal neovascularization, whereas a RORα agonist worsened oxygen-induced retinopathy. Our data demonstrate that RORα is a novel regulator of pathologic retinal neovascularization, and RORα inhibition may represent a new way to treat ocular neovascularization.

subject areas

  • Animals
  • Anti-Inflammatory Agents
  • Cell Proliferation
  • Chromatin Immunoprecipitation
  • Cytokines
  • Heterozygote
  • Homozygote
  • Inflammation
  • Lipids
  • Macrophages
  • Mice
  • Mice, Inbred C57BL
  • Microglia
  • Neovascularization, Pathologic
  • Nuclear Receptor Subfamily 1, Group F, Member 1
  • Oxygen
  • Protein Binding
  • RNA, Messenger
  • Receptors, LDL
  • Retina
  • Retinal Neovascularization
  • Suppressor of Cytokine Signaling Proteins
scroll to property group menus

Research

keywords

  • ROR alpha
  • SOCS3
  • inflammation
  • neovascularization
  • retinopathy
scroll to property group menus

Identity

PubMed Central ID

  • PMC4547221

International Standard Serial Number (ISSN)

  • 0027-8424

Digital Object Identifier (DOI)

  • 10.1073/pnas.1504387112

PubMed ID

  • 26243880
scroll to property group menus

Additional Document Info

start page

  • 10401

end page

  • 10406

volume

  • 112

issue

  • 33

©2021 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support